Medical Marijuana, Inc. (OTCMKTS:MJNA) HempMeds Subsidiary Makes Headway


One cannabis stock that we routinely track and mention on Street Register is Medical Marijuana, Inc. (OTCMKTS:MJNA). The last time we were mentioning it we talked about the company’s Kannaway subsidiary, and its newly launched line of full-spectrum, THC-free hemp oil.

This time, we want to focus more on MJNA’s HempMeds subsidiary, including the recent milestones it has achieved, and a key appearance to be made by the company at a high profile event.

Medical Marijuana, Inc. (OTCMKTS:MJNA) recently revealed that HempMeds is exhibiting at The American Academy of Anti-Aging Medicine (A4M) 25th Annual World Conference which is taking place in Las Vegas for the remainder of the week and through Saturday.

Representatives will reportedly be highlighting HempsMeds’ “Real Scientific Hemp Oil™” (RSHO™) including its CBD hemp oil raw ingredient and zero-THC Real Scientific Hemp Oil-X™ (RSHO-X™), the first-ever cannabis product to receive approval from the federal government of Mexico for importation. Additionally, they will be showcasing the company’s Dixie Botanicals lifestyle supplement consumer-friendly products like stevia-sweetened hemp oil tinctures, vegan capsules, and a topical salve. (Source: PR Newswire)

It would appear that HempMeds products are being well accepted into the marketplace as well, if another recent announcement regarding record revenues is any indicator. It was reported that HempMeds® Mexico generated the largest-ever revenue month in the history of the company in November of 2017, as well as reaching major milestones in its business operations.

HempMeds® Mexico is MJNA’s distribution branch in the country, focusing on providing non-psychoactive cannabidiol products to the people in Mexico. It was in their name that the company’s product was granted approval for import into Mexico, a country that is in the process of restructuring its policies regarding cannabis. This December, Mexican health authorities will publish cannabis regulations for the Mexican market, creating many new investment opportunities and allowing cannabis research to be conducted and cannabis products to be distributed as medicines, herbal remedies, supplements and food.

In November, the company’s president, Raul Elizalde, spoke to the United Nations at the World Health Organization’s Expert Committee Meeting on Drug Dependence, where he urged top global leaders not to schedule CBD as a drug, but rather as a supplement. His appearance gained international media attention and raised awareness for the global need for the expansion of access to CBD.

Elizalde also represented HempMeds® Mexico at the Second International Fair on Medical Cannabis in Colombia. There, he spoke to patients and doctors about the Company’s success and how its products may provide therapeutic benefits to Colombian citizens.

“Our success in Mexico is tremendously important to the Medical Marijuana, Inc. portfolio of companies as we continue to expand our international reach,” said Elizalde. “Mexico has experienced many CBD regulation changes this year and we’re proud to come out of them on top.” (Source: PR Newswire)

Meanwhile, on the chart MJNA is trading above its 50 and 200-day moving averages, having seen a general uptrend since registering its annual lows back in October. Additionally, the company’s Kannaway subsidiary also recently recorded record revenues. Overall we would say MJNA is currently on a promising trajectory. Stay locked to Street Register for updates, and we’ll deliver important developments on MJNA as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!


Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in MJNA stock, short or long.